Novartis, Aveo Spar as Exclusive Antibody Deal Ends

Aveo Pharmaceuticals and Novartis are at odds over how to end a three-year-old, up-to-$326 million exclusive worldwide license agreement to develop and commercialize Aveo’s humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies.In a regulatory filing today, Aveo said Novartis sent the company a notice of termination of the agreement, dated June 29, one day after the biotech sent the pharma giant formal notice of a dispute “reg